• 1
    DeNardo SJ, Kukis DL, Miers L, Winthrop MD, Kroger LA, Salako QA, et al. Yttrium-90-DOTA-peptide ChL6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts. J Nucl Med 1998; 39: 8429.
  • 2
    DeNardo GL, O'Donnell RT, Kroger LA, Richman CM, Goldstein DS, Shen S, et al. Strategies for developing effective radioimmunotherapy for solid tumors. Clin Cancer Res 1999; 10: 321923.
  • 3
    DeNardo SJ, Kukis DL, Kroger LA, O'Donnell RT, Lamborn KR, Miers LA, et al. Synergy of Taxol and radioimmunotherapy with yttrium-90–labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci U S A 1997; 94: 40004.
  • 4
    Basu A, Haldar S. The relationship between Bcl2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod 1998; 4: 1099109.
  • 5
    Harris C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88: 144255.
  • 6
    Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 2006.
  • 7
    Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bel-2 gene. Cancer Res 1994; 54: 31315.
  • 8
    Upadhyay S, Li G, Liu H, Chen YQ, Sarkar FH, Kim HR. bel-2 suppresses expression of p21WAF1/CIP1 in breast epithelial cells. Cancer Res 1995; 55: 45204.
  • 9
    Teixeira C, Reed JC, Pratt MA. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995; 55: 39027.
  • 10
    Haldar S, Basu A, Croce CM. Bcl-2 is the guardian of microtubule integrity. Cancer Res 1997; 57: 22933.
  • 11
    Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994; 69: 1359.
  • 12
    Nunez G, London L, Hockenbery D, Alexander M, Mckearn JP, Korsmeyer SJ. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990; 144: 360210.
  • 13
    McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh J, et al. Expression of the protoonogene bcl-2 in prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 69404.
  • 14
    Poelman SM, Adeyanju MO, Robertson MA, Recant WM, Karrison T, Fleming GF, et al. Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression. Clin Cancer Res 2000; 6: 40438.
  • 15
    Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994; 86: 499504.
  • 16
    Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with Taxol chemotherapy. Clin Cancer Res 2000; 6: 36218.
  • 17
    van Gog FB, Brakenhoff RH, Stigter-van Walsum M, Snow GB, van Dongen GA. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer. Int J Cancer 1998; 77: 138.
  • 18
    Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P, et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 2000; 6: 434350.
  • 19
    O'Donnell R, DeNardo SJ, Miers LA, Kukis DL, Mirick GR, Kroger LA, et al. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts. Cancer Biother Radiopharm 1998; 13: 35161.
  • 20
    Buchsbaum DJ. Experimental radioimmunotherapy. Semin Radiat Oncol 2000; 10: 15667.
  • 21
    DeNardo SJ, Richman CM, Kukis DL, Shen S, Lamborn KR, Miers LA, et al. Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol. Anticancer Res 1998; 18: 40118.
  • 22
    DeNardo SJ, Kroger LA, Lamborn KR, Miers LA, Kukis DL, O'Donnell R, et al. Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma. Cancer 1997; 80(Suppl): 258390.
  • 23
    Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 187886.
  • 24
    Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R1524.
  • 25
    DeNardo SJ, Burke PA, Leigh BR, O'Donnell RT, Miers LA, Kroger LA, et al. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. Cancer Biother Radiopharm 2000; 15: 719.
  • 26
    Dechantsreiter MA, Plankar E, Matha B, Lohof E, Holzemann G, Jonczyk A, et al. N-methylated cyclic RGD peptides as highly active and selective avb3 integrin antagonists. J Med Chem 1999; 42: 303340.
  • 27
    Haubner R, Gratias R, Diefenbach B, Goodman SL, Jonczyk A, Kessler H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin αvβ3 antagonists. J Am Chem Soc 1996; 118: 746172.
  • 28
    Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 115764.
  • 29
    Varner JA. The role of vascular cell integrins αvβ3 and αvβ5 in angiogenesis. EXS 1997; 97: 36190.
  • 30
    Choy H, Akerley W, Glantz M, Safran H, Graziano S, Chung C. Concurrent paclitaxel and radiation therapy for solid tumors. Cancer Control 1996; 3: 3108.
  • 31
    Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183232.
  • 32
    Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Todd DG, Valerie K, Kavanagh BD, et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 1997; 15: 11917.
  • 33
    Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 1999; 10: 2493506.
  • 34
    Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 193540.
  • 35
    Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6: 7018.
  • 36
    Schlagbauer-Wadl H, Klosner G, Heere-Ress E, Waltering S, Moll I, Wolff K, et al. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J Invest Dermatol 2000; 114: 72530.
  • 37
    Galderisi U, Cascino A, Giordano A. Antisense oligonucleotides as therapeutic agents. J Cell Physiol 1999; 181: 2517.
  • 38
    Fell HP, Gayle MA, Yelton D, Lipsich L, Schieven GL, Marken JS, et al. Chimeric L6 anti-tumor antibody: genomic construction, expression, and characterization of the antigen binding site. J Biol Chem 1992; 267: 155528.
  • 39
    Liu AY, Robinson RR, Hellstrom KE, Murray EDJ, Chang CP, Hellstrom I. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci U S A 1987; 84: 343943.
  • 40
    Hellstrom I, Horn D, Linsley P, Brown JP, Brankovan V, Hellstrom KE. Monoclonal antibodies raised against human lung carcinomas. Cancer Res 1986; 46: 391723.
  • 41
    Marken JS, Bajorath J, Edwards CP, Farr AG, Schieven GL, Hellstrom I, et al. Membrane topology of the L6 antigen and identification of the protein epitope recognized by the L6 monoclonal antibody. J Biol Chem 1994; 269: 7397401.
  • 42
    Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82: 124759.
  • 43
    Fan Z, Masui H, Altas I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1993; 53: 43228.
  • 44
    Baselga J, Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 1994; 29: 12738.
  • 45
    Raynaud FI, Orr RM, Goddard PM, Lacey HA, Lancashire H, Judson IR, et al. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther 1997; 281: 4207.
  • 46
    Howell LP, DeNardo SJ, Levy N, Lund J, DeNardo GL. Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: a comparative study. Int J Biol Markers 1995; 10: 12635.
  • 47
    Winthrop MD, DeNardo SJ, Muenzer JT, Chi SG, Gumerlock PH. p53-independent response of a human breast cancer xenograft to radioimmunotherapy. Cancer 1997; 80 (Suppl): 2529–37.
  • 48
    DeNardo SJ, Zhong G-R, Salako Q, Li M, DeNardo GL, Meares CF. Pharmacokinetics of chimeric L6 conjugated to indium-111 and yttrium-90-DOTA-peptide in tumor bearing mice. J Nucl Med 1995; 36: 82936.
  • 49
    Li M, Meares CF, Salako Q, Kukis DL, Zhong G-R, Miers LA, et al. Prelabeling of chimeric monoclonal antibody L6 with 90Yttrium- and 111Indium-1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy. Cancer Res 1995; 55 Suppl: 57268.
  • 50
    Lode HN, Moehler T, Xiang R, Jonczyk A, Gillies SD, Cheresh DA, et al. Synergy between an anti-angiogenic intergrin αv antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc Natl Acad Sci U S A 1999; 96: 15916.
  • 51
    Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother Rep 1966; 50: 21944.
  • 52
    Schwartsmann G, Mans DR, Menke CH, Xavier N, Caleffi M, Ferreira Filho AF, et al. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer. Oncology (Huntingt) 1997; 11: 249.
  • 53
    Frassineti GL, Zoli W, Tienghi A, Ravaioli A, Milandri C, Gentile A, et al. The sequential administration of combined doxorubicin and paclitaxel in the treatment of advanced breast cancer. Semin Oncol 1996; 23: 228.
  • 54
    Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 1993; 37: 3439.
  • 55
    Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WHJ, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85: 132733.
  • 56
    Cotter FE. Antisense therapy for lymphomas. Hematol Oncol 1997; 15: 311.
  • 57
    Webb A, Cunningham D, Cotter F, Clarke PA, Di Stefano F, Ross P, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997; 349: 113741.
  • 58
    DeNardo GL, Kukis DL, Shen S, Mausner LF, Meares CF, Srivastava SC, et al. Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with Burkitt's lymphoma (Raji). Clin Cancer Res 1997;3: 719.
  • 59
    Seiverd C. Hematology for medical technologists. Philadelphia: Lea and Febiger, 1972: 91432.
  • 60
    Agresti A. Categorical data analysis. New York: John Wiley & Sons, 1997: 2837.
  • 61
    Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346: 33640.
  • 62
    Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 56971.
  • 63
    Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin avβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 181522.
  • 64
    Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996; 2: 729.
  • 65
    Lau DH, Xue L, Young LJ, Burke PA, Cheung AT. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 1999; 14: 316.
  • 66
    Klauber N, Parangi S, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol. Cancer Res 1997; 57: 816.
  • 67
    Hockenbery DM. bcl-2 in cancer, development and apoptosis. J Cell Sci 1994; 18: 515.
  • 68
    Reed JC, Kitada S, Takayama S, Miyashita T. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 1994; 5: 615.
  • 69
    Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995; 11: 121728.